Laboratorio Elea S.A.C.I.F. y A.   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Buenos Aires Argentina (1939)
Status: No NME R&D (1939)

Organization Overview

First Clinical Trial
2009
NCT01240447
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Laboratorio Elea Phoenix S.A. | Laboratorio Elea S.A.C.I.F. y A.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 1)

Adenocarcinoma (Phase 2)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Squamous Cell (Phase 2)

Colorectal Neoplasms (Phase 2)

Condylomata Acuminata (Phase 3)

Gastrointestinal Hemorrhage (Phase 2)

Hemorrhage (Phase 2)

HIV Infections (Phase 1)

Immunologic Deficiency Syndromes (Phase 1)

Lung Neoplasms (Phase 3)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Macular Degeneration (Phase 3)

Neuroblastoma (Phase 2)

Retinoblastoma (Phase 1)

Sarcoma, Ewing (Phase 1)

Virus Diseases (Phase 3)

Wilms Tumor (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 21
  • # of Trial APIs: 15